Most Read

The transaction combines two highly-complementary businesses and creates a medical cannabis industry innovator focused on the research and development of advanced cannabinoid treatments. Therapix Biosciences shareholders will receive

RPD designation for progeria and progeroid laminopathies enables priority review voucher (PRV) eligibility upon FDA approval of a rare pediatric disease product application for lonafarnib for these ultra-rare

The GEOMETRY mono-1 study showed an overall response rate (ORR) of 72.0% (95% CI: 50.6-87.9) in treatment-naive patients and 39.1% (95% CI: 27.6-51.6) in previously treated patients. ORR

The committee has recommended Kalydeco to treat people with CF aged 12 to <24 months who have at least one of the following nine mutations in their cystic

For patients with metastatic EGFR-mutated NSCLC, targeted EGFR TKI therapies such as gefitinib, erlotinib, afatinib or osimertinib represent the first-line treatment of choice. However, patients eventually develop resistance

Fibrosis occurs when chronic inflammation or persistent injury leads to the development of excessive connective tissue, which can lead to organ damage and impaired function. Fibrotic diseases can

The $15 million investment will create a center of excellence for early-phase formulation development and clinical trial manufacturing. The Garnet Valley site will focus on developing small molecule

The acquisition strengthens HiFiBiO Therapeutics’ strategic focus on identifying first-in-class targets for multiple immune cell types, as well as applying industry-leading technologies to develop diverse antibody therapeutics. Specific

aGvHD is a leading cause of death following an allogeneic stem cell transplant due to the transplanted immune cells attacking the patient’s tissues. It results in a very